Navigation Links
VirtualScopics Schedules Third Quarter 2012 Earnings Announcement
Date:10/25/2012

ROCHESTER, N.Y., Oct. 24, 2012 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ:   VSCP), a leading provider of quantitative imaging, today announced that before the market opens on Friday, November 9, 2012 it will release its third quarter 2012 financial results. VirtualScopics' President and Chief Executive Officer, Jeff Markin, and Chief Business and Financial Officer, Molly Henderson, will host a conference call that morning at 11:00 a.m. ET to provide a business update and discuss the company's results for the quarter ended September 30, 2012.

Interested participants should call 877-407-8035 when calling within the United States or
+1 201-689-8035 when calling internationally.  This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call.

About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.CONTACTS:

Investor Relations: 

Company Contact:Tim Ryan

Molly HendersonThe Shoreham Group 

Chief Business and Financial Officer, Sr. Vice President80 Eighth Ave, Ste 1107 

500 Linden OaksNew York, NY 10011

Rochester, New York 14625+1 212 242 7777 Direct

+1 585 249.6231tryan@shorehamgroupllc.com 
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Aware, Inc. Reports Third Quarter 2012 Financial Results
2. University of Toronto wins third place at the Gates Foundations Reinvent the Toilet Challenge
3. Infection biology: The elusive third factor
4. Cracking the Neural Code: Third Annual Aspen Brain Forum
5. The Quarterly Review of Biology: Why some fats are worse than others
6. Evermedia Group Announces 375% Increase in Revenue for Second Quarter 2012
7. Medbox, Inc. Releases 2nd Quarter Financials
8. Westlake Chemical Increases Quarterly Dividend By Over 150%
9. Aware, Inc. Reports Second Quarter 2012 Financial Results
10. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
11. One-quarter of grouper species being fished to extinction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: